NVV1 Stock Chart & Stats
€7.75
€0.02(0.32%)
At close: 4:00 PM EDT
€7.75
€0.02(0.32%)
Day’s Range― - ―
52-Week Range€5.44 - €11.84
Previous CloseN/A
Volume826.00
Average Volume (3M)3.03K
Market Cap
€1.88B
Enterprise Value€1.13B
Total Cash (Recent Filing)€719.34M
Total Debt (Recent Filing)€295.60M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 05, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,945,720
10 Day Avg. Volume2,503
30 Day Avg. Volume3,027
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.40Price Target Upside34.25% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€329.07M
Bulls Say, Bears Say
Bulls Say
Proprietary Vaccine Technology PlatformThe recombinant nanoparticle and Matrix-M platforms provide a recurring technology base for developing protein-based vaccines beyond a single product. This can support product extensions, differentiation and partnerships, although future value still depends on successful development and authorization.
Demonstrated Ability To Generate Strong Margins And ProfitsStrong 2025 operating and net margins demonstrate that Novavax can convert vaccine revenue into substantial profitability when demand, pricing and contractual delivery align. That history supports the potential for operating leverage if commercial volumes and product uptake become more consistent.
Partnership Model Broadens Access And MonetizationNovavax’s partnership model can extend manufacturing reach and commercial access without relying solely on its own infrastructure. Contract structures may also diversify monetization through milestones, reimbursements, profit sharing or royalties, supporting scalability when programs advance.
Bears Say
Sustained Revenue DeteriorationThe sharp TTM revenue decline indicates that recent commercial demand and delivery economics have not been stable. Continued top-line contraction would reduce operating leverage, limit resources for research and commercialization, and make future earnings more dependent on new contracts or product launches.
Recurring Cash Burn And External Funding RelianceA multi-year pattern of negative operating and free cash flow shows that the business is consuming cash rather than consistently funding operations internally. Ongoing burn can constrain investment in the pipeline and increase dependence on financing, partner payments or other external sources.
Persistent Stockholders’ Equity DeficitPersistent negative equity weakens the balance sheet’s financial flexibility and makes conventional returns-based measures less meaningful. Combined with liabilities and ongoing cash use, the deficit can restrict capital allocation choices and increase sensitivity to funding needs over coming quarters.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €5.44 and its highest was €11.84 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.88B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -€0.285 earnings per share for the quarter, beating the consensus estimate of -€0.339 by €0.054.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.19.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.285 in its last earnings report, beating expectations of -€0.339. Following the earnings report the stock price went up 0.61%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€10.40 (34.25% Upside)
€10.40 (34.25% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 92%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.42%
12-Months-Change
Fundamentals
Return on Equity
159.85%
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€10.40
▲(34.25% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―